Scholar Rock Files 2023 10-K with Financial Details

Ticker: SRRK · Form: 10-K · Filed: Mar 19, 2024 · CIK: 1727196

Sentiment: neutral

Topics: 10-K, financials, biotech

TL;DR

SRRK 2023 10-K filed. Full financials out, check retained earnings & capital.

AI Summary

Scholar Rock Holding Corp filed its 2023 10-K on March 19, 2024, reporting on its fiscal year ending December 31, 2023. The company, focused on biological products, is based in Cambridge, MA. Key financial data points such as retained earnings, additional paid-in capital, and common stock values for the years 2021, 2022, and 2023 are detailed within the filing.

Why It Matters

This filing provides investors and analysts with a comprehensive overview of Scholar Rock's financial health and performance for the fiscal year 2023, including detailed balance sheet information.

Risk Assessment

Risk Level: medium — As a biotechnology company, Scholar Rock is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What were Scholar Rock's total revenues for the fiscal year ended December 31, 2023?

The provided text does not explicitly state total revenues for the fiscal year ended December 31, 2023. It focuses on balance sheet items and filing metadata.

What is the company's net income or loss for the fiscal year ended December 31, 2023?

The filing excerpt does not contain information regarding the company's net income or loss for the fiscal year ended December 31, 2023.

What significant research and development activities are highlighted in the 2023 10-K?

This specific excerpt of the 10-K filing does not detail research and development activities; it primarily contains metadata and balance sheet account names.

Are there any mentions of new partnerships or collaborations in the 2023 10-K?

The provided text does not mention any new partnerships or collaborations for Scholar Rock Holding Corp.

What is the company's cash and cash equivalents balance as of December 31, 2023?

The excerpt does not specify the cash and cash equivalents balance as of December 31, 2023.

Filing Stats: 4,381 words · 18 min read · ~15 pages · Grade level 18.2 · Accepted 2024-03-19 07:16:49

Key Financial Figures

Filing Documents

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 56 Item 1B. Unresolved Staff Comments 105 Item 1C . Cybersecurity 105 Item 2.

Properties

Properties 106 Item 3.

Legal Proceedings

Legal Proceedings 106 Item 4. Mine Safety Disclosures 106 PART II 107 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities 107 Item 6. Reserved 107 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 108 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 121 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 121 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 121 Item 9A.

Controls and Procedures

Controls and Procedures 121 Item 9B. Other Information 122 Item 9C. Foreign Jurisdictions that Prevent Inspections 122 PART III 123 Item 10. Directors, Executive Officers and Corporate Governance 123 Item 11.

Executive Compensation

Executive Compensation 123 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 123 Item 13. Certain Relationships and Related Transactions, and Director Independence 123 Item 14. Principal Accountant Fees and Services 123 PART IV 124 Item 15. Exhibits and Financial Statement Schedules 124 Item 16. Form 10-K Summary 127 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report"), including the documents incorporated by reference, contains forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", "continue" or the negative of these terms or other comparable terminology. Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include, among others, the following: the success, cost and timing of clinical trials for apitegromab (such as our Phase 3 SAPPHIRE clinical trial) and SRK-181, including the progress, completion, timing of results, and actual results of our clinical trials; the timing, scope, or likelihood of our ability to obtain and maintain regulatory approval from the U.S. Food and Drug A

Business

Item 1. Business I. Overview We are a late-stage biopharmaceutical company focused on the discovery, development and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta ("TGF") superfamily biology, our novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, we believe we may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. Based on this proprietary and scalable technology platform, we are building a growing portfolio of novel product candidates with the aim of transforming the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia. We have discovered and progressed the development of: Apitegromab, an investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle and is being developed for the treatment of spinal muscular atrophy ("SMA"). We also believe apitegromab could have potential in the treatment of other neuromuscular disorders where the inhibition of myostatin may be beneficial. SRK-439, a novel, preclinical, investigational myostatin inhibitor that has high invitro affinity for pro- and latent myostatin and maintains myostatin specificity and is being developed for the treatment of cardiometabolic disorders

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing